Dario Neri: Catalogue data in Autumn Semester 2023 |
| Name | Prof. Dr. Dario Neri |
| Address | Inst. f. Pharmazeutische Wiss. ETH Zürich, HCI H 439 Vladimir-Prelog-Weg 1-5/10 8093 Zürich SWITZERLAND |
| Telephone | +393351003074 |
| dario.neri@pharma.ethz.ch | |
| Department | Chemistry and Applied Biosciences |
| Relationship | Lecturer |
| Number | Title | ECTS | Hours | Lecturers | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 535-0030-00L | Pharmaceutical Immunology II & Therapeutic Proteins  Prerequisites: Either 535-0830-00L Pharmaceutical Immunology I or 551-0317-00L Immunology I must have been taken. | 3 credits | 3G | C. Halin Winter, D. Neri | ||||||||||||||||||||
| Abstract | In this course, various topics related to the development, GMP production and application of therapeutic proteins will be discussed. Furthermore, students will expand their training in pharmaceutical immunology and will be introduced to the basic concepts of pharmaceutical product quality management. | |||||||||||||||||||||||
| Learning objective | Students know and understand: - basic mechanisms and regulation of the immune response - the pathogenic mechanisms of the most important immune-mediated disorders - the concepts of vaccination and cancer immunotherapy - the most frequently used expression systems for the production of therapeutic proteins - the use of protein engineering tools for modifying different features of therapeutic proteins - the mechanism of action of selected therapeutic proteins and their application - basic concepts in the GMP production of therapeutic proteins | |||||||||||||||||||||||
| Content | The course consists of two parts: In the first part, students will complete their training in Pharmaceutical Immunology. This part particularly focuses on the pathogenic mechanisms of immune-mediated diseases, vaccination and cancer immunotherapy. Deepened knowledge of immunology will be relevant for understanding the mechanism of action of many therapeutic proteins, as well as for understanding one major concern related to the use of protein-based drugs, namely, immunogenicity. The second part focuses on topics related to the development and application of therapeutic proteins, such as protein expression, protein engineering, reducing immunogenicity, and GMP production of therapeutic proteins. Furthermore, selected examples of approved therapeutic proteins will be discussed. | |||||||||||||||||||||||
| Lecture notes | Handouts to the lectures will be available for downloading under http://www.pharma.ethz.ch/scripts/index | |||||||||||||||||||||||
| Literature | - Janeway's ImmunoBiology, by Kenneth Murphy (9th or 10th Edition) - Lecture Handouts - Paper References provided in the Scripts - EMEA Dossier for Humira | |||||||||||||||||||||||
| Prerequisites / Notice | Prerequisites: Either 535-0830-00L Pharmaceutical Immunology I or 551-0317-00L Immunology I | |||||||||||||||||||||||
Competencies |
| |||||||||||||||||||||||